nivolumab
bms
['nadim', 'nsclc', 'nivo', 'sclc', 'cm816']
#asco2022 nadim-ii trial (nivo+chemo x 3 neadj, in resectable iiia/b nsclc, egfr/alkwt) by dr. m.provencio significant increase in pcr (primary endpoint, 36.8% vs 6.9%), lower pcr than nadim-i (63%) but in line with cm816 (24%). pd-l1 predictive !! 
MD, PhD, Lead Thoracic Oncol. Unit @hospitalclinic, MedOnc, Prof. @unibarcelona, Researcher Transl Genom ?? Targeted Therapies @IDIBAPS, @EORTC @GECP_org, #LCSM